Research programme: Clostridium difficile antibodies - UCB Pharma

Drug Profile

Research programme: Clostridium difficile antibodies - UCB Pharma

Alternative Names: Humanised IgG1 antibodies - UCB Pharma; UCB Mabs - UCB Pharma

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator UCB Pharma Inc
  • Class Antibodies; Monoclonal antibodies
  • Mechanism of Action Bacterial toxin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Clostridium infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Clostridium-infections in United Kingdom (Parenteral)
  • 12 Sep 2012 Pharmacodynamics data from a preclinical study in Clostridium infections presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2012)
  • 20 Sep 2011 Preclinical trials in Clostridium infections in United Kingdom (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top